Flibanserin
- TRADE NAME: Addyi (Sprout)
- INDICATIONS: Hypoactive sexual desire disorder in premenopausal women
- CLASS: Serotonin type 1A receptor agonist, Serotonin type 2A receptor antagonist
- HALF-LIFE: 11 hours
FDA APPROVAL DATE: 08/18/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alcohol, Amprenavir, Atazanavir, Boceprevir, Carbamazepine, Ciprofloxacin, Clarithromycin, Conivaptan, Digoxin, Diltiazem, Erythromycin, Fluconazole, Fosamprenavir, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telaprevir, Telithromycin, Verapamil
PREGNANCY CATEGORY: N/A
No data available
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of flibanserin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
